Zafgen (NASDAQ:ZFGN) will be issuing its quarterly earnings data after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.
Zafgen (NASDAQ:ZFGN) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.02. On average, analysts expect Zafgen to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
ZFGN traded up $0.12 on Friday, reaching $10.06. The company had a trading volume of 2,051 shares, compared to its average volume of 144,382. The company has a market capitalization of $349.28 million, a P/E ratio of -5.26 and a beta of -0.64. The company has a debt-to-equity ratio of 0.36, a current ratio of 8.42 and a quick ratio of 8.42. Zafgen has a 52-week low of $3.40 and a 52-week high of $12.35.
ZFGN has been the topic of several research reports. BidaskClub raised shares of Zafgen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 27th. Zacks Investment Research raised shares of Zafgen from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. Finally, Wedbush initiated coverage on shares of Zafgen in a research note on Thursday, August 2nd. They set an “outperform” rating and a $14.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $15.25.
A hedge fund recently raised its stake in Zafgen stock. Bank of New York Mellon Corp grew its holdings in shares of Zafgen Inc (NASDAQ:ZFGN) by 45.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 128,320 shares of the biopharmaceutical company’s stock after acquiring an additional 40,194 shares during the quarter. Bank of New York Mellon Corp owned 0.35% of Zafgen worth $1,312,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 72.60% of the company’s stock.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Article: S&P 500 Index
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.